Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26087474 | 0.91 | EPHX2 (0.42) | CXCR3EPHX2 | |
| SCHEMBL30408943 | 0.91 | EPHX2 (0.42) | CXCR3EPHX2 | |
| SCHEMBL26435433 | 0.91 | EPHX2 (0.42) | CXCR3EPHX2 | |
| SCHEMBL26089308 | 0.89 | EPHX2 (0.39) | CXCR3EPHX2TRPV1EPHX1CRBN | |
| SCHEMBL26436130 | 0.89 | EPHX2 (0.39) | CXCR3EPHX2TRPV1EPHX1CRBN | |
| SCHEMBL26090150 | 0.89 | EPHX2 (0.45) | CXCR3EPHX2 | |
| SCHEMBL26435439 | 0.89 | EPHX2 (0.45) | CXCR3EPHX2 | |
| SCHEMBL30407826 | 0.89 | EPHX2 (0.45) | CXCR3EPHX2 | |
| SCHEMBL26435058 | 0.87 | ACHE (0.39) | CXCR3EPHX2TRPV1BRAFKIF11 | |
| SCHEMBL26088923 | 0.86 | PRMT5 (0.40) | CXCR3EPHX2KIF11BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | CXCR3 2666/4885EPHX2 4500/4885TRPV1 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.